New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 31, 2012
12:34 EDTHLF, PFE, CG, BMY, CALM, DUFOn The Fly: Midday Wrap
Stocks on Wall Street were mixed at midday as the last minute fiscal cliff negotiations may prove to be a boost, or a bane, to the averages in the last hours of trading of the year. With little else for investors to key in on, the fiscal cliff headlines will dominate once again for the remainder of the session... ECONOMIC EVENTS: In the U.S. a minor economic report, the Dallas Fed's December manufacturing survey, came in better than expected at +6.8. In China, the HSBC purchasing managersí index for December rose to a final reading of 51.5, an upward revision from the preliminary 50.9 result and an improvement from 50.5 a month earlier... COMPANY NEWS: After Friday's closing bell, the FDA announced it had approved the anti-clotting drug Eliquis, marketed by Bristol-Myers Squibb (BMY) and Pfizer (PFE). Atlantic Equities upgraded Bristol-Myers citing the approval and shares advanced about 1%. Pfizer shares, however, slid about 0.3%... MAJOR MOVERS: Among the notable gainers was Duff & Phelps (DUF), up 20% after agreeing to be acquired by a group led by The Carlyle Group (CG), with the provision that Duff & Phelps can continue to seek a better deal. Also higher were shares of Herbalife (HLF), which rose over 8% as the stock continues to bounce back from the sell-off begun with Bill Ackman's revelation of his short position. Among the noteworthy losers was Cal-Maine Foods (CALM), down 10% after reporting Q2 earnings that missed expectations... INDICES: Near noon, the Dow was down 2.10, or 0.02%, to 12,936.01; the Nasdaq was up 20.07, or 0.68%, to 2,980.38; and the S&P 500 was up 3.80, or 0.27%, to 1,406.23.
News For BMY;PFE;DUF;CG;HLF;CALM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 23, 2015
08:06 EDTBMYBristol-Myers, Rigel enter R&D agreement for TGF beta receptor kinase inhibitors
Rigel Pharmaceuticals (RIGL) and Bristol-Myers Squibb (BMY) announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigelís extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body. The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune systemís activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers Squibbís Opdivo, or nivolumab, and Yervoy, or ipilimumab. Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigelís TGF beta library, including, but not limited to, those approved to treat cancer. Bristol-Myers Squibb will pay $30M upfront and Rigel will be eligible to receive development and regulatory milestones that could total more than $309M for a successful compound approved in multiple indications. Rigel will also be eligible to receive tiered royalties on the net sales of any products from the collaboration.
08:01 EDTBMYBristol-Myers to acquire Flexus, potential total consideration may be $1.25B
Subscribe for More Information
06:09 EDTHLFStocks with implied volatility above IV index mean; ANF HLF
Subscribe for More Information
February 20, 2015
14:04 EDTHLFHerbalife February volatility elevated into Q4 and outlook
Subscribe for More Information
10:33 EDTPFEBattleground update: AbbVie named top global pick at Jefferies
Subscribe for More Information
10:31 EDTPFEPfizer announces FDA acceptance of NDA for Rapamune
Pfizer announced that the FDA has accepted for priority review a supplemental New Drug Application for RAPAMUNE for the treatment of lymphangioleiomyomatosis, a rare, progressive lung disease in women of childbearing age that is often fatal. With the Priority Review designation for the sNDA, Pfizer anticipates a decision in June of 2015 based on the anticipated Prescription Drug User Fee Act action date. The sNDA is based on results from the Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus Trial. The MILES Trial included 89 LAM patients with moderate lung impairment who were randomized to receive RAPAMUNE or placebo for 12 months, followed by a 12 month observation period. In the trial, those treated with RAPAMUNE for one year experienced stabilization of lung function as measured by forced expiratory volume in one second.
07:23 EDTBMY, PFEAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
05:13 EDTHLFStocks with implied volatility above IV index mean; HLF ARCP
Subscribe for More Information
February 19, 2015
18:25 EDTPFEPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
14:49 EDTPFEWalgreens selected by Pfizer as one of pharmacies to dispense Ibrance
Subscribe for More Information
07:12 EDTPFEWharton Health Care Club to hold a conference
Subscribe for More Information
05:31 EDTHLFStocks with implied volatility above IV index mean; HLF ANF
Subscribe for More Information
February 18, 2015
10:05 EDTCGOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Agnico Eagle (AEM) upgraded to Overweight from Neutral at JPMorgan... Amarin (AMRN) upgraded to Buy from Neutral at SunTrust... Capital Product (CPLP) upgraded to Accumulate from Neutral at Global Hunter... Carlyle Group (CG) upgraded to Buy from Neutral at Citigroup... Danone (DANOY) upgraded to Neutral from Underperform at Exane BNP Paribas... Express (EXPR) upgraded on lower promotional activity at Piper Jaffray... Kforce (KFRC) upgraded to Outperform from Market Perform at Avondale... Legg Mason (LM) upgraded to Buy from Hold at Jefferies... Rackspace (RAX) upgraded following Q4 results at Pacific Crest... Rosetta Resources (ROSE) upgraded to Buy from Neutral at Global Hunter... SeaChange (SEAC) upgraded to Buy from Hold at Noble Financial... Valero (VLO) upgraded to Outperform from Neutral at Credit Suisse... Veeco (VECO) upgraded to Buy from Hold at Noble Financial... Wolverine World Wide (WWW) upgraded to Neutral from Underperform at Sterne Agee.
06:08 EDTCGCarlyle Group upgraded to Buy from Neutral at Citigroup
Citigroup upgraded Carlyle Group to Buy saying it believes the company is entering a "robust" harvesting cycle. Citi says Carlyle is at a favorable inflection point and raised its price target for the stock to $32 from $30.50.
February 17, 2015
17:02 EDTHLFSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
15:36 EDTPFETianyin JCM plans for FDA certification process
Tianyin Pharmaceutical (TPI) updated on the business and development at its Jiangchuan Macrolide Facility, or JCM, active pharmaceutical ingredients operation. In addition to JCM's certification at India, along with other international clients located at Bangladesh, Philippines and Iran on import status, TPI plans for FDA certification process at its JCM facility in order to service international clients such as Pfizer's (PFE) and their subsidiaries in China, the company said. "This is expected to translate to further demand for JCM's macrolide API business in both the domestic and international markets," Tianyin stated.
11:49 EDTHLFSoros increased Herbalife stake last quarter amid slide, Bloomberg says
George Sorosí Soros Fund Management increased its stake in Herbalife during the fourth quarter as the stock declined, according to Bloomberg, citing two people familiar with the matter who noted that the firm will disclose details in a filing as early as today. The Fly notes that large investors are given until today by the SEC to disclose their 13F filings outlining their holdings as of the end of the fourth quarter of 2014. Reference Link
11:18 EDTHLFHong Kong women posed as Herbalife presidents, South China Morning Post says
Two women who claimed to be presidents of Herbalife took HK$50M in orders for the company's products from about 60 people before disappearing, according to The South China Morning Post. A number of the victims lost a significant amount of money on the scheme, the newspaper stated. Reference Link
10:01 EDTPFECVS says PCSK9 inhibitors could cost system $150B annually
Subscribe for More Information
09:22 EDTHLFFormer Herbalife distributors to reject $15M settlement, NY Post reports
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use